Neurocrine Biosciences Announces CEO Retirement and Succession
Company Announcements

Neurocrine Biosciences Announces CEO Retirement and Succession

Neurocrine (NBIX) has provided an update.

Neurocrine Biosciences, Inc. has announced the retirement of its current President and CEO, Kevin C. Gorman, Ph.D., slated for October 11, 2024, while confirming that he will remain on the company’s board. Taking his place, Kyle Gano, Ph.D., with a substantial track record in the company and experience in business development, will become the new President and CEO, also joining the board. This leadership transition comes alongside a change in the company’s bylaws to expand the board size to accommodate the new appointment.

For detailed information about NBIX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyNeurocrine’s Ingrezza shows efficacy in Huntington’s Disease Chorea
TheFlyNeurocrine presents data from Ingrezza studies on tardive dyskines patients
TheFlyNeurocrine presents data from long-term KINECT-4 study
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App